COVID-19 – Medxy AI

Ensitrelvir Demonstrates Potent Antiviral Efficacy Comparable to Nirmatrelvir in Early COVID-19: Insights from the PLATCOV Trial

By MedXY 02/25/2026

The PLATCOV trial identifies ensitrelvir as a highly effective oral antiviral, achieving rapid SARS-CoV-2 clearance comparable to ritonavir-boosted nirmatrelvir. This phase 2 adaptive trial suggests ensitrelvir is a viable alternative for outpatient management, potentially overcoming limitations associated with ritonavir-boosted regimens.

Infectious Diseases news Public Health

Beyond Symptom Resolution: Physiological Recovery Lags Behind Subjective Wellness in COVID-19 and Influenza

By MedXY 02/16/2026

A 2-year prospective cohort study reveals that physiological recovery, measured via smartwatches, significantly lags behind self-reported symptom resolution, particularly in moderate-to-severe COVID-19 cases, suggesting a need for revised post-infection activity guidelines and precision monitoring.

Infectious Diseases news Public Health

RSV Frequently Precedes Influenza Peaks: Mapping the Temporal Sequence of the Post-Pandemic Triple-Threat in the United States

By MedXY 02/08/2026

A retrospective study of 148 state-level seasons reveals that RSV typically peaks three weeks before influenza, while COVID-19 lacks consistent seasonality, providing a critical framework for optimizing hospital resource allocation and vaccination timing.

Infectious Diseases news Public Health

2024-2025 COVID-19 Vaccines Provide 79% Protection Against Critical Illness Despite Viral Evolution

By MedXY 02/06/2026

A multicenter study reveals that 2024-2025 COVID-19 vaccines offer 40% protection against hospitalization and 79% against critical illness or death, maintaining efficacy against emerging JN.1 descendants like KP.3.1.1 and XEC.

news Psychiatry Public Health

Beyond the Initial Surge: Critical Lessons for Clinical Mental Health Care from the COVID-19 Pandemic

By MedXY 01/29/2026

This article examines the Lancet Psychiatry Standing Commission's findings on mental health care delivery during COVID-19, highlighting the disproportionate impact on vulnerable groups, the rise of Long COVID, and the urgent need for evidence-based interventions in future global health crises.

Clinical Updates Emergency Medicine news Respiratory

Awake Prone Positioning in COVID-19 Respiratory Failure: A Synthesis of Clinical Trial Evidence and the PROVID Study

By MedXY 01/02/2026

This review synthesizes the findings of the PROVID randomized clinical trial and broader literature, demonstrating that awake prone positioning (APP) significantly reduces the probability of intubation and death in patients with COVID-19 hypoxemic respiratory failure.

Clinical Updates Infectious Diseases news OB/GYN & Women's Health

The Role of COVID-19 Vaccination in Improving Maternal and Perinatal Outcomes: A Comprehensive Review

By MedXY 12/24/2025

Vaccination against SARS-CoV-2 during pregnancy significantly lowers risks of severe maternal COVID-19, hospitalization, critical care admission, and preterm birth across variant periods, underscoring its safety and efficacy for maternal and neonatal health.

Infectious Diseases Internal Medicine news

Targeted Monoclonal Antibody Therapy: Sotrovimab Shows Mortality Benefit in Hospitalized COVID-19 Patients with High Antigen Loads

By MedXY 12/23/2025

The RECOVERY trial demonstrates that sotrovimab significantly reduces 28-day mortality in hospitalized COVID-19 patients with high baseline serum antigen levels, highlighting the potential for biomarker-guided monoclonal antibody therapy despite the challenges of evolving viral variants.

Infectious Diseases news

Ensitrelvir Matches Ritonavir‑Boosted Nirmatrelvir for Rapid SARS‑CoV‑2 Clearance — PLATCOV Phase 2 Results Support an Alternative Oral Mpro Inhibitor

By MedXY 11/23/2025

Phase 2 PLATCOV results show oral ensitrelvir accelerates SARS‑CoV‑2 clearance versus no drug and has antiviral effects close to ritonavir‑boosted nirmatrelvir, supporting further phase 3 evaluation.

Critical Care news Respiratory

Circulating Endothelial Transcriptomic Signatures Predict Worse Outcomes in COVID-19, Respiratory Failure and ARDS

By MedXY 11/07/2025

Transcriptomic deconvolution of blood identifies elevated circulating endothelial signatures (ECS%) that associate with higher 28‑day mortality and worse respiratory trajectories in pediatric respiratory failure and adults hospitalized with COVID‑19.

Critical Care Infectious Diseases news Pediatrics

Surge in Invasive Streptococcus pyogenes Infections Among Children Post-COVID-19: Insights from a Spanish Nationwide Study

By MedXY 10/27/2025

A Spanish multicenter study reveals a sharp rise in pediatric invasive group A streptococcal infections and severity after 2022, highlighting emm1 strain predominance and risk factors for critical illness and mortality.

Infectious Diseases news Pediatrics

Evolving Patterns of Clinical Testing for SARS-CoV-2, Influenza, and RSV in Hospitalized Youths (2016–2024): Insights and Implications

By MedXY 10/27/2025

This study evaluates clinical testing trends for COVID-19, influenza, and RSV among hospitalized children from 2016 to 2024, revealing shifts in testing frequency and identifying factors influencing test utilization.

Internal Medicine news Public Health

Global Mortality Trends 1990-2023: Insights from the GBD 2023 Study on Causes of Death

By MedXY 10/20/2025

The GBD 2023 Study integrates data from 204 countries to reveal shifting global mortality patterns, emphasizing the impact of COVID-19, declining vaccine-preventable deaths, and rising non-communicable diseases, highlighting critical areas for targeted public health action.

Clinical Updates news

Metformin and COVID-19 Symptom Resolution: Evidence from the ACTIV-6 Randomized Clinical Trial

By MedXY 09/11/2025

This review synthesizes recent evidence from the ACTIV-6 trial showing metformin does not significantly reduce symptom duration in low-risk adults with COVID-19, addressing safety, clinical outcomes, and translational insights.

Public Health Specialties

FDA Approves Updated COVID-19 Vaccines Targeting Latest LP.8.1 Variant for High-Risk and Older Adults

By MedXY 08/31/2025

The FDA has authorized updated COVID-19 vaccines from Pfizer and Moderna designed to target the LP.8.1 sublineage, expanding vaccination to adults over 65 and individuals with high-risk conditions, enhancing immune defense against evolving variants.

Psychiatry Public Health Specialties

Depression and Anxiety Rates Increased Among Racial Groups During the Pandemic

By MedXY 08/21/2025

A survey reveals significant increases in depression and anxiety rates among various racial groups during the COVID-19 pandemic, highlighting ongoing racial health disparities.

Infectious Diseases Nephrology news Respiratory Specialties

Kidney-transplant recipients benefit from COVID-19 vaccination

By MedXY 08/20/2025

Kidney-transplant recipients on long-term kidney replacement therapy demonstrate significant reductions in COVID-19-related hospitalizations and mortality following three or more vaccine doses, supporting booster vaccinations in this vulnerable population.

Infectious Diseases Medical News news Respiratory Specialties

Common Cold and Reduced COVID-19 Risk: Insights from the HEROS Cohort Study on Rhinovirus-Induced Airway Antiviral Responses

By MedXY 08/20/2025

Recent rhinovirus infection may nearly halve COVID-19 risk and reduce viral load by triggering airway antiviral gene expression, partially explaining children's milder COVID-19 outcomes.

Clinical Updates Infectious Diseases news Public Health Specialties

Symptomatic Respiratory Disease and COVID-19 Testing Among Healthcare Workers: Insights from the Post-Pandemic Era in Ireland

By MedXY 08/20/2025

A recent Irish study reveals that 6 in 10 healthcare workers with respiratory symptoms test for COVID-19, while vaccination coverage remains low, highlighting ongoing risks and the need for enhanced infection control and vaccination strategies.

Clinical Updates Infectious Diseases news Respiratory Specialties

COVID reinfection may raise risk of persistent symptoms by 35%

By MedXY 08/20/2025

Observational data from the RECOVER Initiative suggest that SARS-CoV-2 reinfection raises the risk of long COVID by 35% relative to single infections, with more recent vaccination potentially mitigating this risk.